Abstract

Vitamin D deficiency is common in the World and Turkey due to changing lifestyles. The association with autoimmune diseases such as obesity, metabolic syndrome, diabetes, cardiovascular diseases and important diseases such as cancer has made it important to prevent vitamin D deficiency. Fetuin-A is a glycoprotein produced in the liver and it is effective in the inhibition of bone mineralization, insulin resistance, obesity and calcification in smooth muscle. In the study conducted, it was aimed to investigate the relationship between the two substances in growth retardation, considering that Vitamin D and Fetuin-A are acting through similar mechanisms. The study was conducted with 50 healthy children with growth retardation. In short patients and underweight patients, vitamin D levels were found to be lower than control group (respectively p = 0,011 p = 0,036). As vitamin D value increased one unit, it was found that the risk of growth retardation decreased by 1,071 times (p = 0,21). Fetuin-A levels were higher in those with growth retardation (p = 0,035). In the preschool group, fetuin-A was higher than middle childhood (p < 0,001). In short patients, fetuin-A levels were higher than control groups (p = 0,043). There was a poor correlation between vitamin D and fetuin-A levels in those with growth retardation (rho: 0,366 p = 0,009). Fetuin-A levels were higher in short children and there was a positive relationship between vitamin D and fetuin-A levels in those with growth retardation. Vitamin D levels were lower in those with growth retardation. 

Keywords: Fetuin-A; Vitamin D; Growth retardation; Underweight, Short stature.

• 33.   Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3(3):e1765.
• 34.   Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, Fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant. 2008;23(10):3263–71.
• 35.   Dziegielewska K, Brown WM, Deal A, Foster KA. The expression of fetuin in the development and maturation of the hemopoietic and immune systems. Histochem Cell Biol. 1996;106(3):319–30.
• 36.   Topsakal S, Akin F, Turgut S, et al. Relationship of apelin, procalcitonin, and Fetuin-A concentrations with carotid intima-media thickness in acromegaly. Ann Clin Biochem. 2015;52(Pt 4):456–61.
• 37.   Karamessinis PM, Malamitsi-Puchner A, Boutsikou T, et al. Marked Defects in the Expression and Glycosylation of 2-HS Glycoprotein/Fetuin-A in Plasma from Neonates with Intrauterine Growth Restriction... Mol Cell Proteomics. 2008;7(3):591–9.
• 38.   Briana DD, Boutsikou M, Gourgiotis D, et al. Serum Fetuin-A/alpha 2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth. J Matern Fetal Neonatal Med. 2008;21(11):826–30.
• 39.   Ashton BA, Smith R. Plasma alpha 2HS-glycoprotein concentration in Paget’s disease of bone: its possible significance. Clin Sci (Lond). 1980;58(5):435–8.
• 40.   Dickson IR, Bagga M, Paterson CR. Variations in the serum concentration and urine excretion of 2HS-glycoprotein, a bone-related protein, in normal individuals and in patients with osteogenesis imperfecta. Calcif Tissue Int. 1983;35(1):16–20.
• 41.   Ix JH, Wassel CL, Bauer DC, et al. Fetuin-A and BMD in older persons: the Health Aging and Body Composition (Health ABC) study. J Bone Miner Res. 2009;24(3):514–21.
• 42.   Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: A prospective follow-up study... Circulation. 1999;99(9):1165–72.
• 43.   Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76(2):4–12.
• 44.   Price PA, Toroian D, Lim JE. Mineralization by inhibitor exclusion: the calcification of collagen with fetuin. J Biol Chem. 2009;284(25):17092–101.
• 45.   Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(11):4479–85.
• 46.   Schaible J, Wigger M, Staude H, et al. Serum Fetuin-A and Vitamin D in children with mild-to-severe chronic kidney disease: A cross-sectional study. Nephrol Dial Transplant. 2012;27(3):1107–13.
• 47.   Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1, 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130(11):2648–52.
• 48.   Nichols E, Khatib I, Aburto N, et al. Vitamin D status and associated factors of deficiency among Jordanian children of preschool age. Eur J Clin Nutr. 2015;69(1):90.
• 49.   Cândido FG, Bressan J. Vitamin D: link between osteoporosis, obesity, and diabetes? Int J Mol Sci. 2014;15(4):6569–91.
• 50.   Manenti L, Vaglio A, Pasquali S. Increased Fetuin-A levels following treatment with a Vitamin D analog. Kidney Int. 2010;78(11):1187.
• 51.   Price PA, Williamson MK, Nguyen TM, Than TN. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem. 2004;279(3):1594–600.
• 52.   Keskin M, Culha C, Gulcelik NE, et al. The evaluation of preoperative and postoperative Fetuin-A levels in patients with primary hyperparathyroidism. Niger J Clin Pract. 2019;22(3):320–7.
• 53.   Santos RS, Coelho FM, Silva BC, et al. Parathyroidectomy Improves Restless Leg Syndrome in Patients on Hemodialysis. PLoS One. 2016;11(5):e0155835.
• 54.   Nimitphong H, Sritara C, Chailurkit LO, et al. Relationship of Vitamin D status and bone mass according to Vitamin D-binding protein genotypes. Nutr J

Data Sharing Statement

Funding